March 20, 2019
Chronic disease management platform Hello Heart will now integrate with LifeScan OneTouch meters as part of its program for diabetes management.
The Redwood City, California-based company started out in hypertension, but has been expanding into diabetes for the past year. OneTouch meters, formerly owned by Johnson & Johnson, are the first of a handful of glucometer brands the company intends...
March 12, 2019
San Francisco-based digital chronic disease managment company Omada Health announced today that it will add fully integrated, cellular-connected glucometers and blood pressure cuffs to its offerings for Type 2 diabetes and hypertension, respectively.
The devices are FDA-cleared and can be mailed to program members. The glucometer will come with as many free test strips as users need, the company...
November 21, 2018
Ascensia Diabetes Care’s Contour Diabetes app — a mobile tool to monitor trends in blood glucose levels that connects to the Contour Next One glucometer — has received yet another update. As of Monday, iPhone users can transfer blood glucose and carbohydrate data from their app to records kept within the Apple Health platform.
After opting in, data collected through Ascensia’s app will...
September 13, 2017
Mountain View, California-based Livongo Health, the chronic condition management technology company founded by former Allscripts CEO Glen Tullman, has acquired Diabeto, a diabetes management company based in Piscataway, New Jersey in the US and Maharashtra in India. The terms of the acquisition were not disclosed.
Though it was founded in 2012, Diabeto really hit the scene in 2015 with an...
May 4, 2015
Johnson & Johnson company LifeScan is launching a clinical trial to determine whether its OneTouch Verio blood glucose meter (or a not-yet-launched version of it) creates a greater reduction in A1C levels when used in conjunction with its companion app.
According to a post on ClinicalTrials.gov, the company is recruiting 148 patients for a randomized control trial that will compare patients...
March 17, 2015
Diabetes management platform Glooko has raised $16.5 million in a round led by Canaan Partners. The round also included a strategic investment from Medtronic as well as funding from additional investors The Social+Capital Partnership and Samsung.
Glooko began by making a cord that connected various glucometers to a user's smartphone. Over time, the company has moved from a connector chord to a...
October 2, 2014
Glooko, which makes a cable that syncs popular glucose meters to a companion app on smartphones, has always said it plans eventually to replace that cable with a wireless Bluetooth connection. Today, the company announced that they've finally released that product, the Bluetooth MeterSync Blue. The small box will plug into a patient's glucose meter and send the information wireless, via Bluetooth...
January 9, 2013
iHealth Labs, a California-based subsidiary of China's Andon Health is expanding its line of iOS-enabled wireless health peripherals, the company announced at CES Las Vegas this week. The company will be adding a wireless blood glucometer and a wireless pulse oximeter to their product offerings, though FDA clearance is still pending for both devices.
iHealth currently makes blood pressure...
November 1, 2011
Sensors for Medicine and Science (SMSI), which is developing an implantable glucose monitoring sensor, announced this week that it received $54.1 million in fourth round funding. Delphi Ventures led the investment, which also included contributions from return backers New Enterprise Associates (NEA), HealthCare Ventures, Anthem Capital and Greenspring Associates.
The company plans to use the...
August 22, 2011
Echo Therapeutics, creator of a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system called Symphony and a transdermal drug delivery system called Prelude SkinPrep, recently debuted a demonstration video on its company website, reports MedGadget. The new video showcases the use of the Symphony system in a home setting and coincides with an upcoming clinical study.